Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) [Yahoo! Finance]
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Bristol Myers Squibb (NYSE:BMY) had its "sector perform" rating reaffirmed by analysts at Scotiabank.
How faster decisions can transform patient care in Canada [Globe and Mail, The (Toronto, Canada)]
Bristol Myers Squibb (NYSE:BMY) was given a new $65.00 price target on by analysts at Truist Financial Corporation.